Evidence changelog.
Every grade change, newly indexed compound, and safety update — dated, explained, and attributable. The audit trail behind the index.
Phase-3 read-outs sustain double-digit weight loss vs. placebo with consistent metabolic effects. Confidence raised from emerging to strong.
NEJM Phase 3 — Retatrutide obesity, 2026 →- BPC-157New evidence
Two new human pilot studies indexed (n=24, n=31). Tier unchanged — still pilot-stage; RCT depth required for upgrade.
- TirzepatideSafety update
Added gallbladder-disease signal to contraindications block following updated label guidance.
Re-review of cited human studies found two were uncontrolled cosmetic-industry trials. Downgraded to anecdotal pending independent replication.
- EpitalonNewly indexed
Newly indexed. Initial grade C — mechanism plausible, long-term human follow-up sparse.
A peptide index without a changelog is a marketing site. We publish every grade change so clinicians and researchers can audit our reasoning. If you disagree with a grade, the citation list on each peptide page is the place to start.